Dermata Therapeutics, Inc. DRMA
0.62 USD -0.04 (-6.01%)
At closeNov 13, 2026, 4:00 PM EST
0.65 +0.03 +4.64%
After hours · Nov 13, 4:00 PM ET
0.5707 Day range 0.6598
0.6212 52-week range 3.14
- YTD
- -73.22%
- 1 year
- -80.22%
News
benzinga.com Dermata Therapeutics Q3 EPS $(0.55), Inline Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(0.55) per share which met the analyst consensus estimate. This is a 66.67 percent increase over losses of $(1.65) per share from the…
benzinga.com Dermata Therapeutics Enrolls First Participant In Its Clinical Trial Evaluating Tome Clearing Treatment For Acne; Expects To Launch This Second Commercial Product In H1 2027 The initiation of this clinical trial marks another milestone in Dermata's strategy by adding a second product to its Tome skincare portfolio, targeting significant opportunities in the consumer…
benzinga.com Why Is Dermata Therapeutics Stock Gaining Thursday? Dermata Therapeutics (DRMA) jumps 34% after positive clinical results for its weekly Bioneedle Tome Foundational Treatment.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Regencell Bioscience (NASDAQ:RGC) stock increased by 30.4% to $10.58 during Thursday's regular session. The company's market cap stands at $4.0 billion. SenesTech (NASDAQ:SNES) stock rose…
benzinga.com Dermata Therapeutics Announces Over 71% Of Patients Had Overall Skin Improvements At Day 29 In Its Cosmetic Clinical Trial Of Tome Foundational Treatment Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced positive topline results from its recently completed cosmetic